Chronic Fatigue Syndrome (CFS)

Categories: Neuronal diseases, Rare diseases

Aliases & Classifications for Chronic Fatigue Syndrome

MalaCards integrated aliases for Chronic Fatigue Syndrome:

Name: Chronic Fatigue Syndrome 12 74 52 54 42 3 15 17 71
Myalgic Encephalomyelitis 12 74 52 3
Postviral Fatigue Syndrome 12 32
Cfs 12 15
Chronic Fatigue Immune Dysfunction Syndrome 52
Systemic Exertion Intolerance Disease 52
Encephalomyelitis, Myalgic 74
Fatigue Syndrome, Chronic 43
Myalgic Encephalitis 12
Chronic Fatigue 6


External Ids:

Disease Ontology 12 DOID:8544
ICD9CM 34 780.71
MeSH 43 D015673
NCIt 49 C3037
SNOMED-CT 67 51771007 52702003
ICD10 32 G93.3 R53.82
UMLS 71 C0015674

Summaries for Chronic Fatigue Syndrome

MedlinePlus : 42 What is chronic fatigue syndrome? Chronic fatigue syndrome (CFS) is a serious, long-term illness that affects many body systems. Another name for it is myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). CFS can often make you unable to do your usual activities. Sometimes you may not even be able to get out of bed. What causes chronic fatigue syndrome? The cause of CFS is unknown. There may be more than one thing that causes it. It is possible that two or more triggers might work together to cause the illness. Who is at risk for chronic fatigue syndrome? Anyone can get CFS, but it is most common in people between 40 and 60 years old. Adult women have it more often that adult men. Whites are more likely than other races to get a diagnosis of CFS, but many people with CFS have not been diagnosed with it. What are the symptoms of chronic fatigue syndrome? CFS symptoms can include Severe fatigue that is not improved by rest Sleep problems Post-exertional malaise (PEM), where your symptoms get worse after any physical or mental activity Problems with thinking and concentrating Pain Dizziness CFS can be unpredictable. Your symptoms may come and go. They may change over time - sometimes they might get better, and other times they may get worse. How is chronic fatigue syndrome diagnosed? CFS can be difficult to diagnose. There is no specific test for CFS, and other illnesses can cause similar symptoms. Your health care provider has to rule out other diseases before making a diagnosis of CFS. He or she will do a thorough medical exam, including Asking about your medical history and your family's medical history Asking about your current illness, including your symptoms. Your doctor will want to know how often you have symptoms, how bad they are, how long they have lasted, and how they affect your life. A thorough physical and mental status exam Blood, urine or other tests What are the treatments for chronic fatigue syndrome? There is no cure or approved treatment for CFS, but you may be able to treat or manage some of your symptoms. You, your family, and your health care provider should work together to decide on a plan. You should figure out which symptom causes the most problems, and try to treat that first. For example, if sleep problems affect you the most, you might first try using good sleep habits. If those do not help, you may need to take medicines or see a sleep specialist. Strategies such as learning new ways to manage activity can also be helpful. You need to make sure that you do not "push and crash." This can happen when you feel better, do too much, and then get worse again. Since the process of developing a treatment plan and attending to self-care can be hard if you have CFS, it is important to have support from family members and friends. Don't try any new treatments without talking to your health care provider. Some treatments that are promoted as cures for CFS are unproven, often costly, and could be dangerous. Centers for Disease Control and Prevention

MalaCards based summary : Chronic Fatigue Syndrome, also known as myalgic encephalomyelitis, is related to irritable bowel syndrome and depression, and has symptoms including muscle weakness, fatigue and fever. An important gene associated with Chronic Fatigue Syndrome is RNASEL (Ribonuclease L), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Dinoprostone and Tocopherol have been mentioned in the context of this disorder. Affiliated tissues include testes, brain and heart, and related phenotypes are behavior/neurological and cardiovascular system

Disease Ontology : 12 A syndrome that involves prolonged and severe tiredness or weariness that is unrelated to exertion, is not relieved by rest and for a minimum of six months and is not directly caused by other conditions.

NIH Rare Diseases : 52 Chronic fatigue syndrome , also known as systemic exertion intolerance disease, is a condition that causes extreme, long-lasting fatigue which can limit the ability to participate in ordinary, daily activities. It generally occurs in young adults (20 to 40 years of age) and is twice as common in women. The main symptom is disabling fatigue that does not improve with rest. Other signs and symptoms may include muscle pain, joint pain, concentration and memory problems, headaches, sleep problems, fever, sore throat, and/or tender lymph nodes . The exact cause is not known. There is still no cure or effective treatment for this condition but there are several clinical trials . There is debate in the medical literature about the relationship between myalgic encephalomyelitis and chronic fatigue syndrome. There is no consensus on nomenclature or classification for these disorders. Different countries, organizations, and researchers continue to use different names to describe these conditions.

CDC : 3 Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a serious, long-term illness that affects many body systems. People with ME/CFS are often not able to do their usual activities. At times, ME/CFS may confine them to bed. People with ME/CFS have severe fatigue and sleep problems. ME/CFS may get worse after people with the illness try to do as much as they want or need to do. This symptom is known as post-exertional malaise (PEM). Other symptoms can include problems with thinking and concentrating, pain, and dizziness.

Wikipedia : 74 Chronic fatigue syndrome (CFS), also referred to as myalgic encephalomyelitis (ME), is a medical... more...

Related Diseases for Chronic Fatigue Syndrome

Diseases related to Chronic Fatigue Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1044)
# Related Disease Score Top Affiliating Genes
1 irritable bowel syndrome 31.7 TNF TLR4 SLC6A4 POMC IL6 IL10
2 depression 31.5 TPH2 SLC6A4 MAOA HTR2A HTR1A CRH
3 sleep disorder 31.4 TNF SLC6A4 POMC IL6 HTR2A HTR1A
4 brucellosis 31.3 TNF TLR4 IL6 IL4 IL2 IL10
5 somatization disorder 31.3 SLC6A4 HTR2A HTR1A CRH
6 encephalitis 31.3 TNF IL6 IL1B IL10
7 ige responsiveness, atopic 31.2 IL4 IL10 IFNG
8 fibromyalgia 31.1 TNF SLC6A4 POMC IL6 IL2 IL1B
9 allergic bronchopulmonary aspergillosis 31.1 IL4 IL10 IFNG
10 neurotic disorder 31.0 SLC6A4 MAOA IL6 HTR2A HTR1A
11 acute stress disorder 31.0 SLC6A4 POMC NR3C1 CRH
12 lyme disease 31.0 TNF IL6 IL1B
13 somatoform disorder 31.0 SLC6A4 IL4 IL1B COMT
14 dysthymic disorder 31.0 SLC6A4 MAOA HTR2A HTR1A CRH
15 alexithymia 31.0 SLC6A4 IL6 IL4 HTR1A COMT
16 sexual disorder 31.0 SLC6A4 POMC HTR2A HTR1A
17 interstitial cystitis 31.0 IL6 IL2 CXCL8
18 haemophilus influenzae 30.9 TNF CXCL8
19 generalized anxiety disorder 30.9 SLC6A4 NR3C1 MAOA HTR2A HTR1A COMT
20 mental depression 30.9 TPH2 SLC6A4 POMC NR3C1 MAOA IL6
21 lung disease 30.9 TNF TLR4 IL6 IL4 IL1B IL10
22 orchitis 30.9 TNF IL6 IL2 IL10
23 brain injury 30.9 IL6 IL10 COMT
24 personality disorder 30.8 TPH2 SLC6A4 NR3C1 MAOA HTR2A HTR1A
25 severe combined immunodeficiency 30.8 IL6 IL4 IL2 IL10 IFNG
26 hypochondriasis 30.8 SLC6A4 POMC HTR2A HTR1A
27 poliomyelitis 30.8 TNF IL4 IL10 IFNG
28 ileus 30.8 TNF POMC IL6 IL1B IL10 IFNG
29 chronic active epstein-barr virus infection 30.8 IL2 IL10 IFNG
30 pharyngitis 30.8 TNF IL6 IL1B CXCL8
31 eating disorder 30.7 SLC6A4 POMC HTR2A CRH COMT
32 allergic rhinitis 30.7 NR3C1 IL4 IL10 IFNG CXCL8
33 rheumatic disease 30.7 TNF IL1B IL10 IFNG
34 restless legs syndrome 30.7 SLC6A4 POMC MAOA IL1B COMT
35 autoimmune disease 30.7 TNF IL6 IL4 IL2 IL1B IL10
36 sleep apnea 30.7 TNF SLC6A4 IL6 IL1B IL10 HTR2A
37 traumatic brain injury 30.6 IL6 IL10 COMT
38 chlamydia pneumonia 30.6 TNF TLR4 IL6 IL10 CXCL8
39 thyroiditis 30.6 TNF IL6 IL4 IL2 IL10
40 narcolepsy 30.6 TNF SLC6A4 MAOA IL6 IL2 HTR2A
41 agoraphobia 30.5 SLC6A4 MAOA HTR2A HTR1A COMT
42 myelitis 30.5 TNF IL6 IL10 CXCL8
43 herpes zoster 30.5 TNF IL2 IL10 IFNG
44 arthropathy 30.5 TNF IL6 IL1B IFNG
45 pericarditis 30.5 TNF IL6 IL1B IFNG CXCL8
46 conduct disorder 30.5 SLC6A4 POMC MAOA COMT
47 systemic onset juvenile idiopathic arthritis 30.5 TNF IL1B
48 mood disorder 30.5 TPH2 SLC6A4 POMC NR3C1 MAOA IL6
49 chickenpox 30.5 TNF IL6 IL4 IL2 IL10 IFNG
50 juvenile rheumatoid arthritis 30.5 TNF IL6 IL2 IL1B IL10 IFNG

Graphical network of the top 20 diseases related to Chronic Fatigue Syndrome:

Diseases related to Chronic Fatigue Syndrome

Symptoms & Phenotypes for Chronic Fatigue Syndrome

UMLS symptoms related to Chronic Fatigue Syndrome:

muscle weakness, fatigue, fever, pruritus, myalgia, back pain, sciatica, muscle cramp, muscle rigidity, muscle spasticity, (non-specific) malaise and fatigue, other malaise and fatigue

MGI Mouse Phenotypes related to Chronic Fatigue Syndrome:

45 (show all 19)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.48 COMT CRH HTR1A HTR2A IFNG IL10
2 cardiovascular system MP:0005385 10.41 COMT HTR1A IFNG IL10 IL1B IL2
3 homeostasis/metabolism MP:0005376 10.4 COMT CRH HTR1A IFNG IL10 IL1B
4 endocrine/exocrine gland MP:0005379 10.35 COMT CRH HTR2A IFNG IL10 IL2
5 cellular MP:0005384 10.34 CRH IFNG IL10 IL2 IL4 IL6
6 growth/size/body region MP:0005378 10.34 CRH IFNG IL10 IL1B IL2 IL4
7 hematopoietic system MP:0005397 10.32 COMT CRH IFNG IL10 IL1B IL2
8 immune system MP:0005387 10.29 COMT CRH IFNG IL10 IL1B IL2
9 integument MP:0010771 10.27 CRH IFNG IL10 IL1B IL4 IL6
10 digestive/alimentary MP:0005381 10.25 HTR2A IFNG IL10 IL2 IL4 IL6
11 nervous system MP:0003631 10.22 COMT CRH HTR1A IFNG IL10 IL1B
12 adipose tissue MP:0005375 10.13 CRH IL6 NR3C1 POMC TLR4 TNF
13 liver/biliary system MP:0005370 10.13 CRH IFNG IL10 IL2 IL4 IL6
14 muscle MP:0005369 10.01 HTR2A IFNG IL10 IL6 NR3C1 SLC6A4
15 neoplasm MP:0002006 9.97 IFNG IL10 IL1B IL2 IL6 POMC
16 no phenotypic analysis MP:0003012 9.96 CRH HTR1A IFNG IL10 IL2 IL4
17 renal/urinary system MP:0005367 9.76 COMT CRH IFNG IL4 IL6 NR3C1
18 respiratory system MP:0005388 9.7 COMT CRH IFNG IL10 IL2 IL4
19 skeleton MP:0005390 9.32 CRH HTR2A IFNG IL10 IL1B IL4

Drugs & Therapeutics for Chronic Fatigue Syndrome

Drugs for Chronic Fatigue Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 305)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Dinoprostone Approved Phase 4 363-24-6 5280360
Tocopherol Approved, Investigational Phase 4 1406-66-2, 54-28-4 14986
leucovorin Approved Phase 4 58-05-9 6006 143
Copper Approved, Investigational Phase 4 7440-50-8 27099
Etoricoxib Approved, Investigational Phase 4 202409-33-4 123619
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
Sodium citrate Approved, Investigational Phase 4 68-04-2
Tetracycline Approved, Vet_approved Phase 4 60-54-8 5353990
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
Polyestradiol phosphate Approved Phase 4 28014-46-2
Levonorgestrel Approved, Investigational Phase 4 797-63-7, 17489-40-6 13109
Naproxen Approved, Vet_approved Phase 4 22204-53-1 1302 156391
Ethanol Approved Phase 4 64-17-5 702
Methyltestosterone Approved Phase 4 58-18-4 6010
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0
Testosterone enanthate Approved Phase 4 315-37-7 9416
Sodium oxybate Approved Phase 4 502-85-2 5360545
tannic acid Approved Phase 4 1401-55-4
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 5785 54670067
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
Methionine Approved, Nutraceutical Phase 4 63-68-3 6137
28 Garlic Approved, Nutraceutical Phase 4
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
30 Tocotrienol Investigational Phase 4 6829-55-6
31 Calcium, Dietary Phase 4
32 Ergocalciferols Phase 4
33 Vitamin D2 Phase 4
34 Calciferol Phase 4
35 Tocopherols Phase 4
36 Tocotrienols Phase 4
37 Iron Supplement Phase 4
38 Cyclooxygenase 2 Inhibitors Phase 4
39 Anti-Inflammatory Agents Phase 4
40 Anti-Inflammatory Agents, Non-Steroidal Phase 4
41 Analgesics, Non-Narcotic Phase 4
42 Antirheumatic Agents Phase 4
43 Analgesics Phase 4
44 Anti-Infective Agents Phase 4
45 Hormone Antagonists Phase 4
46 Hormones Phase 4
47 Dopamine Uptake Inhibitors Phase 4
48 Central Nervous System Stimulants Phase 4
49 Dopamine Agents Phase 4
50 Citrate Phase 4

Interventional clinical trials:

(show top 50) (show all 264)
# Name Status NCT ID Phase Drugs
1 The Effect of Sodium Oxybate in Patients With Chronic Fatigue Syndrome. Unknown status NCT01584934 Phase 4 Sodium oxybate;Placebo
2 The Effect of Nasal CPAP in Patients With Chronic Fatigue and Sleep-disordered Breathing Unknown status NCT01368718 Phase 4
3 The Immune and Clinical Impacts of Vitamin D in Patients With Chronic Musculo-skeletal Pain Unknown status NCT01417923 Phase 4 vitamin D
4 High-dose Ascorbic Acid Intravenous Injection Decreases Mitochondrial DNA Damage in Chronic Fatigue Patients: Randomized-controlled Study Unknown status NCT01926132 Phase 4 ascorbic acid 10g/20ml;Normal Saline 150ml
5 Randomized Cross-Over Trial of Captafer® vs. Oral Iron Sulfate in the Treatment of Iron Deficiency Anemia in Patients With Inflammatory Bowel Disease Unknown status NCT02774057 Phase 4 Captafer®;Iron Sulfate
6 Study Proposal - A Randomized Double-blinded Study Comparing Adding Etoricoxib Versus Placebo to Female Patients With Fibromyalgia-analysis of Organic and Psychiatric Measures Unknown status NCT00755521 Phase 4 etoricoxib
7 Chronic Fatigue Syndrome and Abdominal Symptoms After Giardia Infection: Clinical Evaluation, Biomarkers, Risk Factors and the Effect of Intervention Completed NCT00860236 Phase 4
8 Phase 4 Study of the Use of Sildenafil (Viagra) to Alter Fatigue, Functional Status and Impaired Cerebral Blood Flow in Patients With Chronic Fatigue Syndrome. Completed NCT00598585 Phase 4 Sildenafil (Viagra);Placebo
9 Slow-wave Sleep and Daytime Functioning in Chronic Fatigue Syndrome: Effects of Sodium Oxybate Completed NCT02055898 Phase 4 Sodium Oxybate
10 Use of Lisdexamfetamine Dimesylate in Treatment of Cognitive Impairment (Chronic Fatigue Syndrome): A Double Blind, Placebo Controlled Study Completed NCT01071044 Phase 4 Lisdexamfetamine Dimesylate;Placebo "30, 50 or 70 mg"
11 The Qure Study: Q-fever Fatigue Syndrome - Response to Treatment Completed NCT01318356 Phase 4 Doxycycline;Placebo
12 Effectiveness of S-adenosyl-L-methionine in Patients With Primary Biliary Cirrhosis Completed NCT02557360 Phase 4
13 A Prospective Randomized Trial of Medical Therapy Versus Radiofrequency Endometrial Ablation in the Initial Treatment of Menorrhagia: Treatment Outcomes and Cost Utility Analysis Completed NCT01165307 Phase 4 Estradiol 30mcg / Levonorgestrel 150mcg monophasic oral contraceptive pills;Naproxen sodium pills
14 A Double Blind Randomised Placebo-controlled Trial to Assess the Effect of a Single Administration of Ferric Carboxymaltose of 1000 mg Iron on Glucose Homeostasis, in Iron-deficient Non-anaemic Women of Childbearing Age. Recruiting NCT03191201 Phase 4 Ferric Carboxymaltose;0.9% sodium chloride solution
15 A Placebo-controlled, Randomized, Double-blind, Parallel, Multi-center Clinical Trial to Evaluate the Efficacy and Safety of DA-5515 (Circulan® Soft Cap.) in Patients With Chronic Fatigue Symptoms Due to Impaired Blood Circulation Recruiting NCT03542721 Phase 4 DA-5515;Placebo of DA-5515
16 Thiamin Against Robust IBD Fatigue Active, not recruiting NCT03634735 Phase 4 Thiamine
17 Improving Patient-Important Outcomes With Testosterone Replacement in Hypogonadal Men With a Prior History of Cancer Not yet recruiting NCT04049331 Phase 4 Testosterone cypionate 125 mg/week
18 Phase IV - A Trial of Xyrem in the Treatment of Chronic Fatigue Syndrome. Terminated NCT00498485 Phase 4 Placebo;Sodium Oxybate
19 B-lymphocyte Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome/ Myalgic Encephalopathy (CFS/ME). A Multicentre, Randomized, Double-blind and Placebo Controlled Phase-III Study With Rituximab Induction and Maintenance Treatment. Unknown status NCT02229942 Phase 3 Rituximab;Placebo
20 Clinical Trial, Randomized, Controlled, Parallel, to Evaluate the Effectiveness of Acupuncture as a Treatment in Patients Diagnosed With Chronic Fatigue Syndrome. Unknown status NCT01907711 Phase 2, Phase 3
21 Phase II Role of Immune-pineal Axis in Fibromyalgia: Noradrenergic Modulation and Chronotherapeutic Aspects Unknown status NCT02041455 Phase 2, Phase 3 Melatonin and Placebo;Amitriptyline and Placebo;Melatonin and Amitriptylin
22 Acupuncture for the Treatment of Chronic Post-Chemotherapy Fatigue: a Randomized Phase III Trial Unknown status NCT00658034 Phase 3
23 B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome. A Double-blind, Placebo-controlled Study. Completed NCT00848692 Phase 2, Phase 3 Rituximab;Saline (NaCl 0,9 %) (placebo)
24 A Multi-center, Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of Poly I:Poly C12U (Ampligen®) 400 mg IV Twice Weekly Versus Placebo in Patients With Severely Debilitating Chronic Fatigue Syndrome (CFS)/Myalgic Encephalomyelitis (ME) Completed NCT00215800 Phase 3 Ampligen
25 A Randomized, Placebo-Controlled, Double-Blind Trial of Duloxetine in the Treatment of Patients With Chronic Fatigue Syndrome Completed NCT00375973 Phase 2, Phase 3 Duloxetine;Placebo
26 Randomized, Double-blinded, Placebo-controlled, Multicenter Investigator Initiated Clinical Study to Explore the Efficacy and Safety of GCJBP Laennec Inj.(Human Placenta Hydrolysate) 4ml Per Day 3 Times Per Week for 6 Weeks in the Chronic Fatigue Patients With Chronic Fatigue Syndrome or Idiopathic Chronic Fatigue Completed NCT01742013 Phase 3 GCJBP Laennec Inj.;Placebo
27 Cytokine Inhibition in Chronic Fatigue Syndrome Patients Completed NCT02108210 Phase 2, Phase 3 Anakinra;Placebo
28 A Randomized, Double-blind, Placebo-controlled, Comparative Clinical Trial to Measure the Maximun Heart Rate During a Cycle Ergometer Test After ReConnect® Supplementation in CFS. Completed NCT02063126 Phase 2, Phase 3
29 Pilot, Opened, Randomized Clinical Trial to Assess the Efficacy of Duloxetine in the Treatment of Fibromialgy in Patients With Infection by HIV 1+ Completed NCT00552682 Phase 3 Duloxetine 60 mg, QD
30 Efficacy of High Dose Vitamin C Parenteral Supplement on Amelioration of Fatigue in Company Workers After Work: A Double-Blind, Randomized Controlled Trial Completed NCT00633581 Phase 2, Phase 3
31 A Randomized Placebo-Controlled, Crossover-Design Study of the Effects of Low Dose Naltrexone on Quality of Life as Measured by the Multiple Sclerosis Quality of Life Inventory (MSQLI54) Completed NCT00501696 Phase 3 4.5 mg Naltrexone;Naltrexone
32 CSP#470 - A Randomized, Multi-Center, Controlled Trial of Multi-Modal Therapy in Veterans With Gulf War Illnesses Completed NCT00007748 Phase 3
33 A Randomised, Double Blinded Cross-over Study Comparing the Efficacy of L-carnitine Versus Placebo in the Treatment of Fatigue in Multiple Sclerosis Completed NCT01149525 Phase 3 L-Carnitine;Placebo
34 Study and Treatment of Post Lyme Disease (STOP-LD) Completed NCT00000937 Phase 3 Antibiotics
35 The Effect of ACTH (Acthar) on Measures of Chronic Fatigue in Patients With Relapsing Multiple Sclerosis. Completed NCT02315872 Phase 3 ACTH;Placebo
36 Trial of Inspiratory Muscle Rest and Exercise in Chronic Obstructive Lung Disease Completed NCT00000571 Phase 3
37 Acupuncture for the Treatment of Chronic Post-Chemotherapy Fatigue: A Randomized, Phase III Trial Completed NCT00200096 Phase 3
38 A Prospective, Multicentre, Randomised, Double-blind, Placebo Controlled Study With Oral ST10-021 for the Treatment of Iron Deficiency Anaemia in Subjects With Quiescent Crohn's Disease Where Oral Ferrous Preparations Have Failed or Cannot be Used (AEGIS 2) Completed NCT01352221 Phase 3 ST10;Placebo oral capsule
39 A Prospective, Multicentre, Randomised, Double-blind, Placebo Controlled Study With Oral ST10-021 for the Treatment of Iron Deficiency Anaemia in Subjects With Quiescent Ulcerative Colitis Where Oral Ferrous Preparations Have Failed or Cannot be Used (AEGIS 1) Completed NCT01340872 Phase 3 ST10-021;Placebo Comparator
40 Acupressure for Persistent Cancer-Related Fatigue in Breast Cancer Survivors Completed NCT01281904 Phase 2, Phase 3
41 Phase 3 Study of Qi-tonifying Chinese Herbal Products for Treatment of Allergic Rhinitis Completed NCT01631032 Phase 3 Qi-tonifying Chinese herbal products
42 CSP #403 - Trial of Varicella Zoster Vaccine for the Prevention of Herpes Zoster and Its Complications Completed NCT00007501 Phase 3
43 Randomized Controlled Trial Comparing Two Different Bladder Instillation Treatments for Interstitial Cystitis/Bladder Pain Syndrome Recruiting NCT03463915 Phase 3 Bladder instillation WITH triamcinolone acetonide;Bladder instillation WITHOUT triamcinolone acetonide
44 A Randomized, Double-blind Placebo-controlled Phase III Trial of Coenzyme Q10 in Gulf War Illness Recruiting NCT02865460 Phase 3 Ubiquinol;Placebo
45 The Exercise Response to Pharmacologic Cholinergic Stimulation in Preload Failure Enrolling by invitation NCT03674541 Phase 3 Pyridostigmine
46 A 12-month Prospective, Phase IIIb, Multicenter, Open-label Clinical Trial to Assess Health-related Quality of Life (HRQoL) in Patients With Chronic or High-frequency Episodic Migraine Treated With Erenumab Who Present Associated Comorbidities Not yet recruiting NCT04114630 Phase 3 erenumab 70mg/mL
47 Complementary Treatment of PG2 to Improve Clinical Benefit Response and Quality of Life in Fatigue Terminated NCT00518869 Phase 2, Phase 3 PG2
48 H-36371: Finasteride as a Method of Managing Testosterone-Induced Erythrocytosis Withdrawn NCT02548117 Phase 3 Finasteride
49 Cyclophosphamide in Myalgic Encephalopathy/ Chronic Fatigue Syndrome (ME/CFS). Part A: an Open Label Phase-II Study With Six Intravenous Cyclophosphamide Infusions Four Weeks Apart, and Follow-up for 12 Months Unknown status NCT02444091 Phase 2 Cyclophosphamide
50 Phase 1 + 2a Proof of Concept Study of Treatment of Chronic Fatigue Syndrome (CFS) With Iodinated Activated Charcoal (IodoCarb®) Unknown status NCT01793415 Phase 1, Phase 2 IodoCarb (r)

Search NIH Clinical Center for Chronic Fatigue Syndrome

Inferred drug relations via UMLS 71 / NDF-RT 50 :

coenzyme Q10
Fish Oils
Venlafaxine hydrochloride

Cochrane evidence based reviews: fatigue syndrome, chronic

Genetic Tests for Chronic Fatigue Syndrome

Anatomical Context for Chronic Fatigue Syndrome

MalaCards organs/tissues related to Chronic Fatigue Syndrome:

Testes, Brain, Heart, Lymph Node, Pituitary, Breast, T Cells

Publications for Chronic Fatigue Syndrome

Articles related to Chronic Fatigue Syndrome:

(show top 50) (show all 5625)
# Title Authors PMID Year
Evidence of altered cardiac autonomic regulation in myalgic encephalomyelitis/chronic fatigue syndrome: A systematic review and meta-analysis. 61 42
31651868 2019
Service based comparison of group cognitive behavior therapy to waiting list control for chronic fatigue syndrome with regard to symptom reduction and positive psychological dimensions. 61 42
31574792 2019
Myalgia and chronic fatigue syndrome following immunization: macrophagic myofasciitis and animal studies support linkage to aluminum adjuvant persistency and diffusion in the immune system. 61 42
31059838 2019
Glucocorticoid receptor mediated negative feedback in chronic fatigue syndrome using the low dose (0.5 mg) dexamethasone suppression test. 54 61
18573538 2009
Combined dexamethasone/corticotropin-releasing factor test in chronic fatigue syndrome. 54 61
17803834 2008
Unravelling intracellular immune dysfunctions in chronic fatigue syndrome: interactions between protein kinase R activity, RNase L cleavage and elastase activity, and their clinical relevance. 54 61
18396793 2008
[Overlap between atypical depression, seasonal affective disorder and chronic fatigue syndrome]. 54 61
17546343 2007
Glucocorticoid receptor polymorphisms and haplotypes associated with chronic fatigue syndrome. 54 61
16740143 2007
Inclusion of the glucocorticoid receptor in a hypothalamic pituitary adrenal axis model reveals bistability. 54 61
17300722 2007
Impairments of the 2-5A synthetase/RNase L pathway in chronic fatigue syndrome. 54 61
16277015 2005
2',5'-Oligoadenylate size is critical to protect RNase L against proteolytic cleavage in chronic fatigue syndrome. 54 61
15924878 2005
Fatigue and regulation of the hypothalamo-pituitary-adrenal axis in multiple sclerosis. 54 61
15710856 2005
Variability of the RNase L isoform ratio (37 kiloDaltons/83 kiloDaltons) in diagnosis of chronic fatigue syndrome. 54 61
15699437 2005
Brain 5-HT1A receptor binding in chronic fatigue syndrome measured using positron emission tomography and [11C]WAY-100635. 54 61
15691524 2005
Chronic ACTH autoantibodies are a significant pathological factor in the disruption of the hypothalamic-pituitary-adrenal axis in chronic fatigue syndrome, anorexia nervosa and major depression. 54 61
15885924 2005
Do cytosine guanine dinucleotide (CpG) fragments induce vasoactive neuropeptide mediated fatigue-related autoimmune disorders? 54 61
15922114 2005
Reduction of serotonin transporters of patients with chronic fatigue syndrome. 54 61
15570154 2004
Levels of DHEA and DHEAS and responses to CRH stimulation and hydrocortisone treatment in chronic fatigue syndrome. 54 61
15110921 2004
RNase L levels in peripheral blood mononuclear cells: 37-kilodalton/83-kilodalton isoform ratio is a potential test for chronic fatigue syndrome. 54 61
12626460 2003
Ribonuclease L proteolysis in peripheral blood mononuclear cells of chronic fatigue syndrome patients. 54 61
12118002 2002
Antiviral pathway activation in patients with chronic fatigue syndrome and acute infection. 54 61
11698994 2001
Hypothalamo-pituitary-adrenal axis dysfunction in chronic fatigue syndrome, and the effects of low-dose hydrocortisone therapy. 54 61
11502777 2001
Increased sensitivity to glucocorticoids in peripheral blood mononuclear cells of chronic fatigue syndrome patients, without evidence for altered density or affinity of glucocorticoid receptors. 54 61
11288761 2001
Abnormalities in response to vasopressin infusion in chronic fatigue syndrome. 54 61
11087963 2001
A preliminary study of dehydroepiandrosterone response to low-dose ACTH in chronic fatigue syndrome and in healthy subjects. 54 61
11104854 2000
A randomized, double-blind placebo-controlled trial of moclobemide in patients with chronic fatigue syndrome. 54 61
11030484 2000
A 37 kDa 2-5A binding protein as a potential biochemical marker for chronic fatigue syndrome. 54 61
11126321 2000
Desmopressin augments pituitary-adrenal responsivity to corticotropin-releasing hormone in subjects with chronic fatigue syndrome and in healthy volunteers. 54 61
10356627 1999
Blunted adrenocorticotropin and cortisol responses to corticotropin-releasing hormone stimulation in chronic fatigue syndrome. 54 61
9669518 1998
The low dose ACTH test in chronic fatigue syndrome and in health. 54 61
9713562 1998
A study of the immunology of the chronic fatigue syndrome: correlation of immunologic parameters to health dysfunction. 54 61
9576011 1998
Fibromyalgia, chronic fatigue syndrome, and myofascial pain. 54 61
9567202 1998
Biochemical evidence for a novel low molecular weight 2-5A-dependent RNase L in chronic fatigue syndrome. 54 61
9243369 1997
Changes in growth hormone, insulin, insulinlike growth factors (IGFs), and IGF-binding protein-1 in chronic fatigue syndrome. 54 61
9046989 1997
Changes in the 2-5A synthetase/RNase L antiviral pathway in a controlled clinical trial with poly(I)-poly(C12U) in chronic fatigue syndrome. 54 61
7893988 1994
Upregulation of the 2-5A synthetase/RNase L antiviral pathway associated with chronic fatigue syndrome. 54 61
8148461 1994
Assessment of the scientific rigour of randomized controlled trials on the effectiveness of cognitive behavioural therapy and graded exercise therapy for patients with myalgic encephalomyelitis/chronic fatigue syndrome: A systematic review. 61
31072121 2020
Can the light of immunometabolism cut through "brain fog"? 61
32039912 2020
Treating medically unexplained symptoms via improving access to psychological therapy (IAPT): major limitations identified. 61
32020880 2020
Correction: Obesity in adolescents with chronic fatigue syndrome: an observational study. 61
31969354 2020
Associations of occupational stress, workplace violence and organizational support on chronic fatigue symptoms among nurses. 61
32011012 2020
Myalgic encephalomyelitis/chronic fatigue syndrome patients exhibit altered T cell metabolism and cytokine associations. 61
31830003 2020
Guided graded Exercise Self-help for chronic fatigue syndrome: patient experiences and perceptions. 61
30325677 2020
Post-exertional malaise is associated with greater symptom burden and psychological distress in patients diagnosed with Chronic Fatigue Syndrome. 61
31884303 2020
Assessing diagnostic value of microRNAs from peripheral blood mononuclear cells and extracellular vesicles in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. 61
32034172 2020
Identification of actin network proteins, talin-1 and filamin-A, in circulating extracellular vesicles as blood biomarkers for human myalgic encephalomyelitis/chronic fatigue syndrome. 61
31759091 2020
Comprehensive Circulatory Metabolomics in ME/CFS Reveals Disrupted Metabolism of Acyl Lipids and Steroids. 61
31947545 2020
Metabolic analysis of amino acids and vitamin B6 pathways in lymphoma survivors with cancer related chronic fatigue. 61
31923274 2020
Myalgic Encephalomyelitis - Time to repent. 61
31968124 2020
Is the efficacy of repetitive transcranial magnetic stimulation influenced by baseline severity of fatigue symptom in patients with myalgic encephalomyelitis. 61
31483181 2020

Variations for Chronic Fatigue Syndrome

ClinVar genetic disease variations for Chronic Fatigue Syndrome:

6 ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 MT-CO3 NC_012920.1:m.9355A>TSNV Uncertain significance 523307 rs1556423663 MT:9355-9355 MT:9355-9355

Expression for Chronic Fatigue Syndrome

Search GEO for disease gene expression data for Chronic Fatigue Syndrome.

Pathways for Chronic Fatigue Syndrome

Pathways related to Chronic Fatigue Syndrome according to GeneCards Suite gene sharing:

(show top 50) (show all 87)
# Super pathways Score Top Affiliating Genes
Show member pathways
Show member pathways
13.78 TNF TLR4 NR3C1 IL6 IL4 IL2
Show member pathways
13.6 TNF IL6 IL4 IL2 IL1B IL10
Show member pathways
Show member pathways
13.49 TNF TLR4 IL6 IL4 IL2 IL1B
Show member pathways
13.37 TNF IL6 IL4 IL2 IL1B IL10
Show member pathways
13.29 TNF TLR4 NR3C1 IL4 IL2 IL1B
Show member pathways
Show member pathways
13.01 TNF IL6 IL4 IL2 IL1B IL10
Show member pathways
Show member pathways
Show member pathways
12.78 TNF TLR4 IL6 IL2 IL1B
Show member pathways
12.77 TNF TLR4 IL6 IL4 IL2 IL1B
Show member pathways
12.76 TNF TLR4 IL6 IL4 IL2 IL1B
Show member pathways
12.73 TNF IL6 IL2 IL1B IL10 IFNG
17 12.73 TNF RNASEL IL4 IL2 IL1B IL10
Show member pathways
12.71 TNF IL4 IL2 IL10 IFNG
Show member pathways
Show member pathways
Show member pathways
12.48 IL6 IL4 IL2 IL10 IFNG
Show member pathways
Show member pathways
12.46 TNF IL6 IL2 IL10 CXCL8
24 12.44 TNF TLR4 IL1B CXCL8
Show member pathways
26 12.42 TNF TLR4 IL6 IL1B CXCL8
28 12.4 TNF TLR4 IL6 IL1B IL10 IFNG
Show member pathways
12.36 TNF IL6 IL2 IL1B IL10
Show member pathways
Show member pathways
Show member pathways
12.33 TNF TLR4 IL6 CXCL8
Show member pathways
Show member pathways
36 12.27 TNF TLR4 IL6 IFNG
Show member pathways
38 12.18 TNF IL6 IL4 IL2 IL10 IFNG
Show member pathways
12.18 TNF TLR4 IL6 IL2 IL1B IL10
41 12.13 TNF TLR4 IL6 IL2 IL1B IL10
Show member pathways
12.09 IL4 IL2 IL1B IFNG
44 12.06 TLR4 POMC IL2 CXCL8 CRH
46 12.04 TNF TLR4 IL1B CXCL8
47 12.03 TNF IL6 IL1B CXCL8
48 12.03 TNF IL6 IL4 IL1B
49 12.01 TNF TLR4 IL6 IL1B IL10 IFNG
50 12 TNF TLR4 IL6 IL4 IL2 IL1B

GO Terms for Chronic Fatigue Syndrome

Cellular components related to Chronic Fatigue Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.65 TNF POMC IL6 IL4 IL2 IL1B
2 extracellular space GO:0005615 9.32 TNF POMC IL6 IL4 IL2 IL1B

Biological processes related to Chronic Fatigue Syndrome according to GeneCards Suite gene sharing:

(show top 50) (show all 64)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.25 TLR4 POMC NR3C1 IL6 IL4 IL1B
2 positive regulation of transcription by RNA polymerase II GO:0045944 10.1 TNF TLR4 RNASEL POMC NR3C1 IL6
3 positive regulation of cell proliferation GO:0008284 10.09 IL6 IL2 IL1B IFNG HTR2A HTR1A
4 response to drug GO:0042493 10.07 SLC6A4 IL10 HTR2A CRH COMT
5 response to lipopolysaccharide GO:0032496 10 TLR4 IL1B IL10 COMT
6 inflammatory response GO:0006954 10 TNF TLR4 IL6 IL1B IL10 CXCL8
7 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.99 TNF TLR4 IL6 IL1B
8 positive regulation of protein phosphorylation GO:0001934 9.98 TNF IL2 IL1B IFNG CRH
9 positive regulation of DNA-binding transcription factor activity GO:0051091 9.95 TNF IL6 IL1B IL10
10 positive regulation of inflammatory response GO:0050729 9.92 TNF TLR4 IL2 IL1B
11 cellular response to lipopolysaccharide GO:0071222 9.91 TNF TLR4 IL6 IL1B IL10 CXCL8
12 regulation of insulin secretion GO:0050796 9.89 TNF IL1B IFNG
13 response to estrogen GO:0043627 9.89 TPH2 CRH COMT
14 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.89 TNF TLR4 IL1B
15 negative regulation of tumor necrosis factor production GO:0032720 9.88 TLR4 POMC IL10
16 humoral immune response GO:0006959 9.88 TNF IL6 IFNG
17 response to glucocorticoid GO:0051384 9.88 TPH2 TNF IL6 IL10
18 positive regulation of phagocytosis GO:0050766 9.87 TNF IL1B IFNG
19 positive regulation of T cell proliferation GO:0042102 9.87 IL6 IL4 IL2 IL1B
20 positive regulation of interleukin-6 production GO:0032755 9.86 TNF TLR4 IL6 IL1B
21 positive regulation of gene expression GO:0010628 9.86 TNF TLR4 SLC6A4 IL6 IL4 IL1B
22 positive regulation of B cell proliferation GO:0030890 9.85 TLR4 IL4 IL2
23 negative regulation of interleukin-6 production GO:0032715 9.85 TNF TLR4 IL10
24 positive regulation of interleukin-6 secretion GO:2000778 9.84 TNF TLR4 IL1B
25 lipopolysaccharide-mediated signaling pathway GO:0031663 9.84 TNF TLR4 IL1B
26 positive regulation of JAK-STAT cascade GO:0046427 9.83 TNF IL6 IL10
27 negative regulation of neurogenesis GO:0050768 9.82 TNF IL6 IL1B
28 positive regulation of interleukin-8 production GO:0032757 9.82 TNF TLR4 IL1B
29 positive regulation of nitric oxide biosynthetic process GO:0045429 9.8 TNF TLR4 IL1B IFNG
30 positive regulation of chemokine production GO:0032722 9.79 TNF TLR4 IL6
31 positive regulation of glial cell proliferation GO:0060252 9.79 TNF IL6 IL1B
32 astrocyte activation GO:0048143 9.78 TNF IL1B IFNG
33 positive regulation of interferon-gamma production GO:0032729 9.78 TNF TLR4 IL2 IL1B
34 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.77 TNF IL1B IFNG
35 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.77 TNF IL1B IL10
36 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.77 TNF IL6 IL4 IL2 IFNG
37 behavior GO:0007610 9.73 HTR2A HTR1A
38 negative regulation of amyloid-beta clearance GO:1900222 9.73 TNF IFNG
39 positive regulation of isotype switching to IgG isotypes GO:0048304 9.73 IL4 IL2
40 negative regulation of tumor necrosis factor biosynthetic process GO:0042536 9.73 IL4 IL10
41 neurotransmitter catabolic process GO:0042135 9.73 MAOA COMT
42 catecholamine metabolic process GO:0006584 9.73 MAOA COMT
43 dopamine catabolic process GO:0042420 9.72 MAOA COMT
44 negative regulation of lipid storage GO:0010888 9.72 TNF IL6
45 serotonin receptor signaling pathway GO:0007210 9.72 HTR2A HTR1A
46 endothelial cell apoptotic process GO:0072577 9.72 TNF IL10
47 regulation of establishment of endothelial barrier GO:1903140 9.71 TNF IL1B
48 positive regulation of neuroinflammatory response GO:0150078 9.71 TNF IL6 IL1B
49 negative regulation of cytokine secretion involved in immune response GO:0002740 9.7 TNF IL10
50 neuroinflammatory response GO:0150076 9.7 IL4 IFNG

Molecular functions related to Chronic Fatigue Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.46 IL6 IL4 IL2 IL10
2 cytokine activity GO:0005125 9.23 TNF IL6 IL4 IL2 IL1B IL10
3 serotonin binding GO:0051378 9.13 SLC6A4 HTR2A HTR1A

Sources for Chronic Fatigue Syndrome

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
54 Novoseek
57 OMIM via Orphanet
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....